Cartesian Therapeutics (RNAC) Return on Equity: 2016-2025
Historic Return on Equity for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to 4.36%.
- Cartesian Therapeutics' Return on Equity rose 22.00% to 4.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.36%, marking a year-over-year increase of 22.00%. This contributed to the annual value of 0.35% for FY2024, which is 92.00% down from last year.
- Cartesian Therapeutics' Return on Equity amounted to 4.36% in Q3 2025, which was down 33.02% from 6.52% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Return on Equity ranged from a high of 12.07% in Q4 2024 and a low of -7.26% during Q4 2021.
- In the last 3 years, Cartesian Therapeutics' Return on Equity had a median value of 1.86% in 2024 and averaged 2.99%.
- As far as peak fluctuations go, Cartesian Therapeutics' Return on Equity slumped by 32,534bps in 2021, and later spiked by 1,080bps in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Return on Equity stood at -7.26% in 2021, then spiked by 750bps to 0.24% in 2022, then skyrocketed by 103bps to 1.27% in 2023, then skyrocketed by 1,080bps to 12.07% in 2024, then rose by 22bps to 4.36% in 2025.
- Its last three reported values are 4.36% in Q3 2025, 6.52% for Q2 2025, and 3.09% during Q1 2025.